Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Viking - I second that - leucro made the most substantive and accurate contribution on here - not even worth coming on this board any more...just watch from afar with my investment.
and you would be posting this here because?
Two partners are...
Mid-Gulf Recovery Services about 3 weeks ago
and
Hornbeck Offshore Services this past week.
Mid-Gulf has the relationships already with BP and has vessels, Hornbeck has the barges and vessels to bring the equipment to the site in the gulf do they can set up their operation closer to the leak.
With this trio of a team - they can be in action by Wednesday of this week.
CNN - great interview, Frederika gave them a good amount of time to explain the process - the CEO did a better job of it - good thing was he mentioned 2 meetings with BP in last few weeks, explained the the two partner companies have the vessels to handle the process with ESPNs equipment - sounds like they are very close - most encouraging interview yet. Bledsoe did a great job also. IMO we get a contract within next 2 weeks. GLTA
Good work chm....
This is better than we have seen and encouraging.
YES!!! Let's get this going to P E N N I E S!!! Slap dat ask...you too London.
Dak77 - I added too - good opportunity to get this to what level - I forgot what you said about that level? :)
Ken Glynn
908 788 0077
He takes calls and wants to be available and speak with shareholders and those interested...and there may be a machine on because they are getting numerous calls. If he doesn't call back - please don't go on and on in th\is board that he is missing in action, doesn;t care, etc - just call back and get the result or answer you want. GLTA
Familyof5 - It's 10am on the east coast - he is in his office - call him back...talking to us and continuing to post this does not accomplish what you want in the long run, Just call him and get your question answered first hand.
Ken is not missing in action - we have numerous shareholders on this board that just yesterday posted of their conversations with him.
I'm in now on this one - 1.5M order in at 9 and got filled at 85 also. Patience here for the news - may add more if any other dips but looks like it has settled here.
sure is - got 500k with proceeds from some sells i did on dead weight. Gonna be rockin again - bright future here.
Picked up a lot more today on these dips - didn't think I'd ever get this oppotunity again - won't see them later for sure.
It is Ken Glynn's book he wrote on patent's - and he published it through his company "Glynntech Inc"
end of conversation - thanks for confirming this with KG - now let's move on with getting this thing moving in the right direction - UP.
It's lunchtime - sheez
Everything is in the iBox - great DD, contact info, etc
Carpenterguy, thanks for the update.
Re: his being debarred, my understanding is he was disbarred for 6 months in 2004 for a small amount of money in a client trsust fund case. He was not permanantly disbarred. In that case he denied many of the allegations and accepted some.
Good work Dak - good update - adds to Ken's crdibility in handling each and every detail - very upfront guy...and sounds like with every start-up - he is doing it on his own. Unusual also in that he is available and communicates. We've got a good one here.
Thanks HSP - few hurdles there - GLTY
where is resistance on the chart today? anyone?
The volume of proposals going into BP is unreal....
Clean Beach Technologies system was one of 80,000 submitted to BP Of all those responses, 250 made the cut to be tested in the field, according to BP spokesman Mark Poegler.
A staff of 40 people is assigned to separate the wheat from the chaff. Fully 7,000 different proposals got to where the technicians thought they deserved more considerations.
Poegler said that of tens of thousands of responses, about 60% involved plugging the well. The other 40% involved dealing with the oil at the surface.
Here is full story
http://www.ibtimes.com/articles/28165/20100611/bp-readies-tests-cleanup-ideas.htm
Right you are - I have read and reread this and what most still don't understand is that the solar charger is one of four coming out in a few weeks - we haven't even heard what the other 3 are. If they understood this is just the first of countless steps ken is taking in lauching and growing our business.
(Flemington, NJ) – Ken Glynn, President of SpeechSwitch, Inc. (PINKSHEETS:SSWC), announced today that the company will launch the Kenergy™ Solar Recharger for recharging iPods®, iPhones® and other small electronic devices. The very portable Kenergy™ Solar Recharger attaches to mobile phones and other devices to recharge their batteries. The device itself is solar rechargeable and needs no outlet to recharge the iPod® or iPhone®. The Kenergy™ device weighs in at only 45 grams, and includes a 5v, 60 mA solar panel. It will retail at $ 37.50 and undercut competitive products. The launch, along with three other existing solar chargeable products, is planned for July 7, 2010. Marketing will be multifaceted and will include internet and magazine advertising, as well as a live sales team who will seek retail outlets for wholesale arrangements. (* iPod® and iPhone® are trademarks of Apple, Inc. The Kenergy™ Solar Recharger is not an Apple product. Kenergy™ is a trademark of SpeechSwitch, Inc
The patent for ken's solar charger has to be different than what's already on the market - could have an edge up on the technology of similar devices that are on the market - most prices run somewhere between high teens to eighty bucks and more depending on what it's packaged with.
This is the first retail item - more and more to come.
Good work Ken for getting out a PR as promised - that a shift - a CEO keeping a promise.
GLTA
Dak77 - wow - this is gonna blow - huge market here - more than we imagined.
NEWS! Ecosphere files patent to raise BP oil to surface
What a terrific comparison - the story unfolds in such a way of much bigger possibilities.
and thanks for the almost 24/7 presence you are on the site - you rarely see the Mod making things happen like you and taking a alewdership role in empowering the process.
I have never been involved in a run like this - but I've got my seatbelt on and ready for take-off. Like you say - slap that ask - GLTA
Looking forward...with continued DD and Dak77 has the ibox looking great, we are getting ready for the ride of the year. GLTA
FOX NEWS - last to be interviewed, logo and mae very visible both on the equipment and his shirt - machine is very impressive - not sure why President of company was on and not with the inventor Dennis who is very verbal - must say machine was very impressive. Being last will make ESPH more memorable. Wouldn't talk about whether BP was working with them - he only talked about the "partner" hard to find an argument why BP or the government wouldn;t want to use them.
xbigshot1 - excellent 8 minutes spent watching your video - between you, jimmybob and rainmaker & others we have the bases of DD covered here. Quite a group - I feel fortunate to be in on this and meet you (in cyberspace no less). Thanks and GLTY
Excellent reporting Vulcan - exposure, exposure & exposure and we will get there yet. This is a gem in the waiting. I've got 1M also - so bachers beware I am putting you on ignore.
Ecosphere to be featured on Mike Huckabee’s TV show on the Fox News Channel
Saturday, June 12, 2010 at 8:00pm Eastern Standard Time, Ecosphere Technologies (OTCBB:ESPH) will be featured on Mike Huckabee’s TV show on the Fox News Channel. The “Huckabee” show will discuss a number of ways to clean up the BP oil spill including Ecosphere’s solution. The show will also be replayed on Saturday, June 12, 2010 at 11:00pm EST and on Sunday at 8:00pm EST.
Thanks for your work here jimmybob - your comments and insight give credence to the "story" as it unfolds. Appreciate it for myself and others.
Right on leucro - the doubt and pessimism is uncalled for - your contribution of your own DD to satisfy and then increse your investment to the level of major shareholder to this board is excellent. ASt every step you were a gentleman and when there was doubt you scanned proof - you have been above board with disclosing your shares purchased and even loaded up screen prints of your personal account transactions.
Enough of this - please - we are here to support each other and make some money. He doesn;t have to disclose anything - this board has the momentum it has due to his leadership - there are others, but he is a constant here.
For me and I know many others, we thank you leucro. If you need a break from this negativity take it - we understand, but do return soon - we need you and your leadership.
APP Pharmaceuticals to Market Oxaliplatin Injection (Liquid) in the U.S.
Date : 06/11/2010 @ 1:01AM
Source : Business Wire
Stock : APP Pharmaceuticals, Inc. (APCVZ)
Quote : 0.1338 0.0 (0.00%) @ 7:22AM
APP Pharmaceuticals to Market Oxaliplatin Injection (Liquid) in the U.S.
Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ) announced today that APP Pharmaceuticals will immediately begin marketing Oxaliplatin Injection (liquid) in the U.S. The U.S. Food and Drug Administration granted approval to market Oxaliplatin Injection in two dosage strengths to Fresenius Kabi Oncology Limited (NSE: FKONCO) (BSE: 532545). APP Pharmaceuticals and Fresenius Kabi Oncology Limited are members of the Fresenius Kabi Group of companies. APP currently markets the lyophilized product, Oxaliplatin for Injection, 50 mg and 100 mg.
Oxaliplatin Injection is therapeutically equivalent to the reference-listed drug Eloxatin®, which is currently marketed by the innovator sanofi-aventis. Under the terms of the previously announced settlement agreement with sanofi-aventis, which covers patents that apply to Eloxatin®, APP Pharmaceuticals and Fresenius Kabi Oncology Limited may market liquid and lyophilized Oxaliplatin products through at least June 30, 2010 and resume marketing the products on August 9, 2012.
According to IMS data, U.S. sales of Eloxatin® in 2009 were $993 million1. According to 2009 IMS data, combined U.S. sales of Eloxatin® and generic oxaliplatin were approximately $1.35 billion1.
Eloxatin® is approved for the adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor and treatment of advanced carcinoma of the colon or rectum. APP will market Oxaliplatin Injection in 5 mg/mL single dose vials, available in 10 mL and 20 mL vial sizes. APP's Oxaliplatin Injection is bar-coded, preservative-free and latex-free.
“This approval enables APP to offer its customers a choice between the lyophilized product that APP currently markets and a more convenient, ready to use liquid form,” said John Ducker, President and Chief Executive Officer of APP Pharmaceuticals. “Adding Oxaliplatin Injection to our product offerings further expands APP’s growing Oncology portfolio.”
About APP Pharmaceuticals, Inc.
APP Pharmaceuticals, Inc. is a fully-integrated pharmaceutical company that develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. The company offers one of the most comprehensive product portfolios used in hospitals, long-term care facilities, alternate care sites and clinics within North America and manufactures a comprehensive range of dosage formulations. Fresenius Kabi Pharmaceuticals Holding, Inc., a wholly owned subsidiary of Fresenius Kabi AG, acquired APP Pharmaceuticals, Inc. on September 10, 2008. For more information about APP Pharmaceuticals, Inc., please visit the company’s Web site at www.APPpharma.com.
Fresenius Kabi Oncology Limited
Fresenius Kabi Oncology Limited is one of the leading companies for cancer research and anti-cancer products. Leveraging the global outreach through integration with Fresenius Kabi, Fresenius Kabi Oncology Limited is benchmarking the oncology excellence with world class production, state-of-the-art manufacturing and research & development facilities. Fresenius Kabi Oncology Limited has world class expertise for the development and manufacturing of active pharmaceutical ingredients, intermediates and oral & injectable finished dosage forms.
About Fresenius Kabi AG
Fresenius Kabi AG is the leader in infusion therapy and clinical nutrition in Europe and in its most important countries of Latin America and Asia Pacific. Fresenius Kabi’s core product range includes infusion solutions, blood volume substitutes, I.V. drugs and parenteral nutrition, as well as products for enteral nutrition. Furthermore, the company provides concepts for ambulatory health care and is focused on managing and providing home therapies. With the philosophy “caring for life” and a comprehensive product portfolio, the company aims at improving the quality of life of critically and chronically ill patients all over the world. In 2009, Fresenius Kabi achieved sales of EUR 3,086 million and an operating profit of EUR 607 million. For more information visit the company’s Web site at www.fresenius-kabi.com. Fresenius Kabi AG is a 100% subsidiary of Fresenius SE.
Forward-Looking Statement
The statements contained in this news release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this news release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the demand, supply and distribution of our products. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements. Additional relevant information concerning risks are discussed under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Fresenius Kabi Pharmaceuticals Holding, Inc. 10-K for the fiscal year ending December 31, 2009 and other documents the company has filed with the Securities and Exchange Commission.
The information contained in this news release is as of the date of this release. Fresenius Kabi Pharmaceuticals Holding, Inc. does not assume any obligation to update or revise these forward-looking statements to conform the statement to actual results, new information, developments or changes in the Company’s expectations.
1 Per IMS Dataview © IMS HEALTH as of December 31, 2009
Eloxatin® is a registered trademark of sanofi-aventis.
Congratulations all - extraordinary accomplishment. WoW!!
iHub's quotes are 15 minutes delayed - not real time
I'm showing .0009 with 2.1 Million trades
Every day a few more gifts under the tree!! You are digging up gold here - the great thing is that he has not let all his trove of treasures all out at once. Makes for many PRs in the future.
This tree is going to bear a lot of fruit. Good work as always Rainmaker - Many thanks
Brilliant report and thanks for making the call for us. We're going to have to put you on the payroll. Much appreciated.